|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.595 USD | -4.67% |
|
-6.42% | +8.89% |
| 11-06 | Earnings Flash (VNDA) VANDA PHARMACEUTICALS Reports Q3 Revenue $47.7M | MT |
| 11-06 | Vanda Pharmaceuticals Inc., Q3 2024 Earnings Call, Nov 06, 2024 |
| Capitalization | 281M 267M 248M 220M 398M 23.85B 441M 3.09B 1.14B 9.79B 1.06B 1.03B 42.74B | P/E ratio 2024 * |
-15.2x | P/E ratio 2025 * | 129x |
|---|---|---|---|---|---|
| Enterprise value | 92.15M 87.7M 81.28M 72.29M 130M 7.82B 145M 1.01B 374M 3.21B 346M 338M 14.01B | EV / Sales 2024 * |
0.46x | EV / Sales 2025 * | 1.27x |
| Free-Float |
96.85% | Yield 2024 * |
-
| Yield 2025 * | - |
More valuation ratios
* Estimated data
More news
Last Transcript: Vanda Pharmaceuticals Inc.
More recommendations
More press releases
More news
| 1 day | -4.67% | ||
| 1 week | -6.42% | ||
| Current month | -10.78% | ||
| 1 month | -13.95% | ||
| 3 months | -7.73% | ||
| 6 months | -23.16% | ||
| Current year | +8.89% |
1 week
4.55
4.95
1 month
4.555.55
Current year
3.466.75
1 year
3.466.75
3 years
3.3018.00
5 years
3.3021.86
10 years
3.3033.44
| Director | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 64 | 30/04/2003 | |
Kevin Moran
DFI | Director of Finance/CFO | 40 | 14/03/2020 |
Scott Howell
HRO | Human Resources Officer | - | 31/07/2019 |
| Manager | Title | Age | Since |
|---|---|---|---|
Richard Dugan
BRD | Director/Board Member | 82 | 30/11/2005 |
| Chairman | 64 | - | |
Stephen Mitchell
BRD | Director/Board Member | 72 | 13/02/2020 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.34% | 28 M€ | +13.79% | ||
| 0.22% | 26 M€ | +10.25% | - | |
| 0.05% | 0 M€ | 0.00% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi. ($) | ||
|---|---|---|---|---|---|---|
| -4.67% | -6.42% | +23.19% | -70.94% | 281M | ||
| -0.73% | +2.76% | +31.80% | +125.70% | 122B | ||
| -1.61% | +3.89% | -8.21% | +16.32% | 84.78B | ||
| -0.89% | -1.39% | +38.79% | +121.12% | 37.38B | ||
| -3.05% | +1.99% | +17.32% | -54.25% | 28.97B | ||
| -1.71% | +13.18% | -23.72% | -59.01% | 23.29B | ||
| -10.78% | -10.58% | +5.55% | -38.27% | 22.06B | ||
| -0.32% | +1.63% | -29.57% | -38.21% | 14.67B | ||
| -3.91% | +1.18% | +756.19% | +262.50% | 13.76B | ||
| +0.05% | +3.58% | +9.64% | +63.13% | 13.07B | ||
| Average | -2.79% | +2.11% | +82.10% | +32.81% | 36.03B | |
| Weighted average by Cap. | -1.91% | +2.66% | +41.11% | +59.18% |
| 2024 * | 2025 * | |
|---|---|---|
| Net sales | 198M 189M 175M 156M 281M 16.82B 311M 2.18B 804M 6.91B 744M 728M 30.14B | 272M 259M 240M 213M 385M 23.06B 427M 2.99B 1.1B 9.47B 1.02B 998M 41.33B |
| Net income | -18.72M -17.82M -16.51M -14.69M -26.51M -1.59B -29.38M -206M -75.9M -652M -70.28M -68.77M -2.85B | 4.57M 4.35M 4.03M 3.58M 6.47M 388M 7.17M 50.17M 18.52M 159M 17.15M 16.78M 695M |
| Net Debt | -189M -180M -167M -148M -268M -16.03B -296M -2.07B -766M -6.58B -709M -694M -28.72B | 65.1M 61.96M 57.42M 51.07M 92.2M 5.52B 102M 715M 264M 2.27B 244M 239M 9.9B |
More financial data
* Estimated data
Employees
203
Calendar
04/02/2025
- Q4 2024 Earnings Release (Projected)
| Date | Price | Change | Volume |
|---|---|---|---|
| 10/12/24 | 4.595 $ | -4.67% | 1,424,944 |
| 09/12/24 | 4.820 $ | -0.41% | 616,584 |
| 06/12/24 | 4.840 $ | +1.26% | 659,777 |
| 05/12/24 | 4.780 $ | -1.24% | 538,068 |
| 04/12/24 | 4.840 $ | -1.43% | 760,474 |
Delayed Quote Nasdaq, December 10, 2024 at 08:30 pm
More quotes
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
4.820USD
Average target price
10.43USD
Spread / Average Target
+116.34%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- VNDA Stock
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition